Clinical Trials Browser

Pathologic Complete Response × Azacitidine × 1 year × Clear all

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 2 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute